Abbott and Novo Nordisk enter partnership to provide integrated digital solution to people with diabetes using insulin
- Details
- Category: Novo Nordisk
Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLink[1] mobile app and LibreView[2] cloud-based system).
Ochsner Health System and Pfizer partner to develop innovative models for clinical trials
- Details
- Category: Pfizer
NEW ORLEANS & Ochsner Health System, Louisiana's largest non-profit academic healthcare system, and Pfizer Inc (NYSE:PFE) have entered into a multi-year strategic alliance to develop innovative models for clinical trials.
Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease
- Details
- Category: Novartis
Novartis announced that the US Food and Drug Administration (FDA) has approved Egaten® (triclabendazole) for the treatment of fascioliasis in patients six years of age and older. This makes Egaten the only FDA-approved drug for people with this disease and is expected to facilitate broader access to this important drug not only in the US, but also in affected countries worldwide.
Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)
- Details
- Category: Bayer
Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and commercialization, including the U.S., for larotrectinib (VITRAKVI®) and BAY 2731954 (LOXO-195). Both compounds are being developed globally for the treatment of adult and pediatric patients with advanced solid tumors harboring NTRK gene fusions.
Boehringer Ingelheim (Canada) Ltd. and IBM Canada announce first of its kind collaboration to integrate blockchain technology into clinical trials
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim (Canada) Ltd. and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology in clinical trials. This collaboration underscores Boehringer Ingelheim's commitment to healthcare innovation and marks the first time that blockchain technology will be explored in a clinical trial setting in Canada.
Merz delivers double-digit growth in strategic business areas
- Details
- Category: Business
Merz, a global leader in aesthetics and neurotoxins, showed substantial growth across both of its strategic focus areas at the end of its most recently completed fiscal year 2017/18. Merz's aesthetics and specialty neurology businesses both increased by 19 percent versus prior year, excluding foreign exchange impact. Together, these two areas now account for 67 percent of the company's healthcare revenue.
The Union for International Cancer Control and Pfizer announce new phase of global grants initiative supporting metastatic breast cancer patients
- Details
- Category: Pfizer
In conjunction with World Cancer Day, the Union for International Cancer Control (UICC) and Pfizer Inc. announce the third round of the Seeding Progress And Resources for the Cancer Community (SPARC): Metastatic Breast Cancer (MBC) Challenge: their pioneering grants initiative designed to
More Pharma News ...
- Merck to expand US biopharmaceutical R&D facility to advance innovative clinical pipeline
- US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897
- Forxiga receives positive EU CHMP opinion for the treatment of adults with type-1 diabetes
- Pfizer receives positive CHMP opinion for Vizimpro® (dacomitinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR-activating mutations
- Merck Granted U.S. Patent for novel combination of Artificial Intelligence and Blockchain Technology
- Pfizer and Lilly announce top-line results from second Phase 3 study of tanezumab in osteoarthritis pain
- Amgen receives NMPA approval for Repatha® (evolocumab) In China to reduce the risk of cardiovascular events